Research programme: tuberculosis therapeutics - Lilly TB Drug Discovery InitiativeAlternative Names: BIKAKEN; CPZEN-45
Latest Information Update: 24 Feb 2015
At a glance
- Originator Eli Lilly; Lilly TB Drug Discovery Initiative; Microbial Chemistry Research Foundation; Summit plc
- Class Nucleosides; Small molecules
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Tuberculosis